IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v13y2022i1d10.1038_s41467-022-28674-1.html
   My bibliography  Save this article

Investigation of Cas9 antibodies in the human eye

Author

Listed:
  • Marcus A. Toral

    (Stanford University
    University of Iowa)

  • Carsten T. Charlesworth

    (Stanford University)

  • Benjamin Ng

    (Stanford University
    University of Oxford)

  • Teja Chemudupati

    (Stanford University)

  • Shota Homma

    (Stanford University)

  • Hiromitsu Nakauchi

    (Stanford University
    Stanford University School of Medicine
    University of Tokyo)

  • Alexander G. Bassuk

    (University of Iowa)

  • Matthew H. Porteus

    (Stanford University)

  • Vinit B. Mahajan

    (Stanford University
    Veterans Affairs Palo Alto Health Care System, Palo Alto, CA)

Abstract

Preexisting immunity against Cas9 proteins in humans represents a safety risk for CRISPR–Cas9 technologies. However, it is unclear to what extent preexisting Cas9 immunity is relevant to the eye as it is targeted for early in vivo CRISPR–Cas9 clinical trials. While the eye lacks T-cells, it contains antibodies, cytokines, and resident immune cells. Although precise mechanisms are unclear, intraocular inflammation remains a major cause of vision loss. Here, we used immunoglobulin isotyping and ELISA platforms to profile antibodies in serum and vitreous fluid biopsies from human adult subjects and Cas9-immunized mice. We observed high prevalence of preexisting Cas9-reactive antibodies in serum but not in the eye. However, we detected intraocular antibodies reactive to S. pyogenes-derived Cas9 after S. pyogenes intraocular infection. Our data suggest that serum antibody concentration may determine whether specific intraocular antibodies develop, but preexisting immunity to Cas9 may represent a lower risk in human eyes than systemically.

Suggested Citation

  • Marcus A. Toral & Carsten T. Charlesworth & Benjamin Ng & Teja Chemudupati & Shota Homma & Hiromitsu Nakauchi & Alexander G. Bassuk & Matthew H. Porteus & Vinit B. Mahajan, 2022. "Investigation of Cas9 antibodies in the human eye," Nature Communications, Nature, vol. 13(1), pages 1-9, December.
    • Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-28674-1
    DOI: 10.1038/s41467-022-28674-1
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-28674-1
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-022-28674-1?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Julie M. Crudele & Jeffrey S. Chamberlain, 2018. "Cas9 immunity creates challenges for CRISPR gene editing therapies," Nature Communications, Nature, vol. 9(1), pages 1-3, December.
    2. Lucas B. Harrington & David Paez-Espino & Brett T. Staahl & Janice S. Chen & Enbo Ma & Nikos C. Kyrpides & Jennifer A. Doudna, 2017. "A thermostable Cas9 with increased lifetime in human plasma," Nature Communications, Nature, vol. 8(1), pages 1-8, December.
    3. Jonathan Strecker & Sara Jones & Balwina Koopal & Jonathan Schmid-Burgk & Bernd Zetsche & Linyi Gao & Kira S. Makarova & Eugene V. Koonin & Feng Zhang, 2019. "Engineering of CRISPR-Cas12b for human genome editing," Nature Communications, Nature, vol. 10(1), pages 1-8, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Qiao Liu & Di He & Lei Xie, 2019. "Prediction of off-target specificity and cell-specific fitness of CRISPR-Cas System using attention boosted deep learning and network-based gene feature," PLOS Computational Biology, Public Library of Science, vol. 15(10), pages 1-22, October.
    2. Xiangfeng Kong & Hainan Zhang & Guoling Li & Zikang Wang & Xuqiang Kong & Lecong Wang & Mingxing Xue & Weihong Zhang & Yao Wang & Jiajia Lin & Jingxing Zhou & Xiaowen Shen & Yinghui Wei & Na Zhong & W, 2023. "Engineered CRISPR-OsCas12f1 and RhCas12f1 with robust activities and expanded target range for genome editing," Nature Communications, Nature, vol. 14(1), pages 1-13, December.
    3. Zhiheng Yang & Zilong Li & Bixiao Li & Ruihong Bu & Gao-Yi Tan & Zhengduo Wang & Hao Yan & Zhenguo Xin & Guojian Zhang & Ming Li & Hua Xiang & Lixin Zhang & Weishan Wang, 2023. "A thermostable type I-B CRISPR-Cas system for orthogonal and multiplexed genetic engineering," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    4. Chady H. Hakim & Sandeep R. P. Kumar & Dennis O. Pérez-López & Nalinda B. Wasala & Dong Zhang & Yongping Yue & James Teixeira & Xiufang Pan & Keqing Zhang & Emily D. Million & Christopher E. Nelson & , 2021. "Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models," Nature Communications, Nature, vol. 12(1), pages 1-12, December.
    5. Zhangyi Luo & Yixian Huang & Neelu Batra & Yuang Chen & Haozhe Huang & Yifei Wang & Ziqian Zhang & Shichen Li & Chien-Yu Chen & Zehua Wang & Jingjing Sun & Qiming Jane Wang & Da Yang & Binfeng Lu & Ja, 2024. "Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapy," Nature Communications, Nature, vol. 15(1), pages 1-20, December.
    6. Greta Bigelyte & Joshua K. Young & Tautvydas Karvelis & Karolina Budre & Rimante Zedaveinyte & Vesna Djukanovic & Elizabeth Ginkel & Sushmitha Paulraj & Stephen Gasior & Spencer Jones & Lanie Feigenbu, 2021. "Miniature type V-F CRISPR-Cas nucleases enable targeted DNA modification in cells," Nature Communications, Nature, vol. 12(1), pages 1-8, December.
    7. Colin McGaw & Anthony J. Garrity & Gabrielle Z. Munoz & Jeffrey R. Haswell & Sejuti Sengupta & Elise Keston-Smith & Pratyusha Hunnewell & Alexa Ornstein & Mishti Bose & Quinton Wessells & Noah Jakimo , 2022. "Engineered Cas12i2 is a versatile high-efficiency platform for therapeutic genome editing," Nature Communications, Nature, vol. 13(1), pages 1-11, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-28674-1. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.